1 . Rudd P. In search of the gold standard for compliance measurement [editorial]. Arch Intern Med 1979;139:627-628.
2. Kass MA. Compliance and prognosis in glaucoma [editorial]. Arch Ophthalmol 1985;103:504.
3. Kass MA, Gordon M, Meltzer DW Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy. Am J Ophthalmol 1986;101: 524-530.
4. Van Buskirk EM. The compliance factor [editorial]. Am J Ophthalmol 1986;101: 609-610.
5. Sclar DA. Improving medication compliance: a review of selected issues. Clin Ther 1991;13:436-440.
6. Ashburn FS, Goldberg 1, Kass MA. Compliance with ocular therapy. Surv Ophthalmol 1980;24:237-248.
7. Cramer JA, Mattson RH, Prevey IVIL, et al. How often is medication taken as prescribed: a novel assessment technique. J Am Med Assoc 1989;261:3273-3277. Published erratum appears in J Am Med Assoc 11989;262:1472.
8. Weintraub M. Promoting patient compliance: role of health professionals, government, and the pharmaceutical industry. NY State J Med 1975;Oct:2263-2266.
9. Weintraub M. Compliance in the elderly. Clin Geriatr Med 1990;6:445-452.
10. Sclar DA, Skaer TL, Cin A, et al. Effectiveness of the C Cap in promoting prescription refill compliance among patients with glaucoma. Clin Ther 1991;13:396-400.
11. Sverrisson T, Gross R, Pearson J, et al. The dorzolamideltimolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. J Glaucoma 1999;8:315-324.
12. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes on noncompliance by patients prescribed eyedrops. Br J Ophthalmol 1990;74:477-480.
13. Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine. Am J Ophthalmol 1986;101:515-523.
14. Granström PA. Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects. BrJ Ophthalmol 1982;66:464-470.
15. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye 1998;12:234-236.
16. Brown MM, Brown GC, Spaeth GL. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol 1984;19:2-5.
17. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Sury Ophthalmol 1983;28 (Suppl.):252-257.
18. Rosenthal AR, Zimmerman JF, Tanner J. Educating the glaucoma patient. Br J Ophthalmol 1983;67:814-817.
19. Schenker H, Maloney S, Liss C, et al. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Ther 1999;21:138-147.
20. Bucci MG and the Italian Latanoprost Study Group. Intraceular pressurelowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomised, observer-masked multicenter study in patients with open-angle glaucoma. J Glaucoma 1999;8:24-30.
21. Smith SL, Pruitt CA, Sine CS, et al. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 1999;77:189-192.